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Abstract: Photodynamic Therapy (PDT) with methyl-aminolevulinate (MAL-PDT) is being
used for the treatment of Basal Cell Carcinoma (BCC), although resistant cells may appear.
Normal differentiated cells depend primarily on mitochondrial oxidative phosphorylation (OXPHOS)
to generate energy, but cancer cells switch this metabolism to aerobic glycolysis (Warburg effect),
influencing the response to therapies. We have analyzed the expression of metabolic markers
(β-F1-ATPase/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) ratio, pyruvate kinase M2
(PKM2), oxygen consume ratio, and lactate extracellular production) in the resistance to PDT of
mouse BCC cell lines (named ASZ and CSZ, heterozygous for ptch1). We have also evaluated the
ability of metformin (Metf), an antidiabetic type II compound that acts through inhibition of the
AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway to sensitize
resistant cells to PDT. The results obtained indicated that resistant cells showed an aerobic glycolysis
metabolism. The treatment with Metf induced arrest in the G0/G1 phase and a reduction in the lactate
extracellular production in all cell lines. The addition of Metf to MAL-PDT improved the cytotoxic
effect on parental and resistant cells, which was not dependent on the PS protoporphyrin IX (PpIX)
production. After Metf + MAL-PDT treatment, activation of pAMPK was detected, suppressing the
mTOR pathway in most of the cells. Enhanced PDT-response with Metf was also observed in ASZ
tumors. In conclusion, Metf increased the response to MAL-PDT in murine BCC cells resistant to
PDT with aerobic glycolysis.
Keywords: basal cell carcinoma; photodynamic therapy; resistance; metabolic markers; metformin
1. Introduction
Basal cell carcinoma (BCC) is the most common skin cancer worldwide, and its incidence rate has
increased in recent decades [1]. BCC is generally slow-growing and rarely metastasizes; however, it can
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be highly destructive and mutilating to local tissues, and its recurrence rate at five years is quite high,
about 20% [2,3].
The main treatment for BCC involves surgical modalities associated with disfigurement. Since BCC
usually appears in photo-exposed areas, such as face or extremities, noninvasive therapies such as
Photodynamic Therapy (PDT) have been developed for its treatment [3].
PDT is approved in the clinic for the treatment of several forms of non-melanoma skin cancer [4],
and there are several clinical trials for gastrointestinal and prostate carcinomas, among other type of
cancers [5,6]. PDT is a two-step therapy: (i) administration of a photosensitizer (PS) and (ii) tumor
irradiation with light of a specific wavelength that generates reactive oxygen species (ROS) that
destroy tumor cells [7–10]. One of the compounds approved for its use in oncological dermatology is
methyl-aminolevulinate (MAL), a precursor of the endogenous PS protoporphyrin IX (PpIX). MAL is
approved for the treatment of actinic keratosis (AKs) in the U.S. and the E.U. and for superficial and
nodular BCC and Bowen’s disease in the E.U. [8,10].
However, PDT is not always effective and recurrences may occur after the treatment [3].
Normal differentiated cells depend primarily on mitochondrial oxidative phosphorylation (OXPHOS)
to generate energy, but cancer cells switch this metabolism to an enhanced aerobic glycolysis, a process
known as Warburg effect [11]. Changes during the reprogramming of cellular metabolism have
been correlated, among other events, with changes in the expression of the β-catalytic subunit of the
mitochondrial H+-ATP synthase (β-F1-ATPase), which is the bottleneck of OXPHOS, relative to
the expression of glycolytic glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in different
neoplasia [12,13]. It has been described that Warburg effect could influence the response to antitumor
drugs [14–16]. In addition, it has been observed (i) that pyruvate kinase M2 (PKM2) is highly expressed
in cancers and promotes cell survival [17] and (ii) that phosphoinositide 3-kinase signaling via
protein kinase B (AKT) is able to regulate glucose transporter expression (GLUT1), enhancing glucose
capture [18]. In addition, the mammalian target of rapamycin (mTOR) seems to play a significant role
in the metabolic reprogramming of tumor cells, specifically mTOR complex 1 (mTORC1), which is
activated in the majority of cancers [19].
One possible solution to avoid recurrences in PDT is its combination with other treatments.
Since changes in cell metabolism occur in cancer cells, the use of compounds that regulate the glucose
metabolism could be an excellent option to reduce relapses. In this sense, metformin (Metf), used in type
2 diabetes mellitus, has become a promising drug in oncology, acting, particularly through inhibition of
the AMP-activated protein kinase (AMPK)/mTOR pathway [20,21]. In skin cancer, it has been described
that Metf inhibits tumor promotion (papillomas and squamous cells carcinomas) in overweight and
obese mice downstream of mTORC1 [22]. In addition, other studies have demonstrated that Metf
enhanced the cytotoxicity of PDT with 5-aminolevulinic acid in lung cancer cells [23] and reduced
angiogenesis and tumor inflammation in combination with 20-tetra-sulfophenyl-porphyrin-PDT in
Walker 256 carcinosarcomas induced in rats [24].
The present study evaluates the metabolic reprogramming in two BCC murine cell lines (named
ASZ and CSZ) resistant to PDT and the adjuvant effect of Metf to this therapy in vitro on these two
murine cell lines and in vivo in tumors generated by injecting ASZ cells.
2. Results
2.1. Cells Survival Evaluation after PDT
The mouse cell lines named ASZ and CSZ were used, both heterozygous for the ptch1 gene [25].
The cells, called parental (P), were subjected to 10 PDT cycles (1 mM methyl-aminolevulinate,
followed by red light irradiation) to obtain resistant cells (10 G). Resistant cells were inoculated
in immunosuppressed mice; the induced tumors were subcultured by explants, and a cell population
called 10 GT was obtained (Figure S1) [2]. After generation of resistant populations of BCC
murine cells (ASZ and CSZ), their resistance to PDT was validated, in terms of cell survival, by
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the 3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazoliumbromide (MTT) assay. The obtained data
confirmed, as expected, that 10 G populations of ASZ and CSZ cells were more resistant to PDT than
their respective P populations. In addition, 10 GT CSZ cells were significantly more resistant than
their respective P and 10 G populations; however, this was not observed with 10 GT of ASZ cells that
showed a lower resistance than their corresponding P and 10 G (Figure 1a,b). For all the experiments,
the corresponding controls were performed: untreated cells (cells without MAL or light irradiation)
and cells treated with MAL (0.2 mM, 5 h) or red light alone (15.2 J/cm2); no cell toxicity was detected.
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Figure 1. Cell survival after Photodynamic Therapy (PDT): Survival of P, 10 G, and 10 GT populations
of (a) ASZ and (b) CSZ cell lines subjected to methyl-aminolevulinate (MAL)-PDT and evaluated by the
3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazoliumbromide (MTT assay). MTT test was performed
24 h after PDT treatment (0.2 mM MAL for 5 h and subsequently exposed to variable doses of red light).
The 10 G population showed the highest resistance to treatment in ASZ cell lines, whereas in CSZ,
it was the 10 GT population. Values were represented as mean ± SD (* p < 0.05; ** p < 0.01; *** p < 0.001)
(n = 5).
According to these results, we selected the 10 G population of ASZ and the 10 GT of CSZ cells as
resistant cells to PDT to perform the rest of the experiments. In addition, to evaluate the synergic effect
with Metf, conditions of MAL-PDT that induced in the P populations a DL30 (lethal dose of 30%) were
selected (0.2 mM MAL and 7.6 J/cm2 in ASZ and 3.8 J/cm2 in CSZ cells).
2.2. Proliferation Capacity and Metabolic Characterization
By using the clonogenic assay, e tested the proliferativ capacity of each cell population by
evaluating the siz of the colonies formed: small (<1 mm), medium (1–2 mm), a d large (>2 mm).
The results obtain d with ASZ w re in agreement with those previously published by our group [2],
indicating that P and 10 G of ASZ cells formed a higher number of small coloni s than their respective
CSZ cells. However, ASZ did not show differences in size between P and the resistan cells; the sa e
happened with the col nies of CSZ. Therefore, we cannot as ociate increase in cell prolif ra ion
with the resistance to PDT (Figure 2a).
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Figure 2. Proliferation capacity and metabolic characterization of Basal Cell Carcinoma (BCC) cells:
(a) For the clonogenic assay, 50 cells/mL were seeded in each plate of 6 wells, and 7 days later, the colonies
formed were stained with 0.2% crystal violet. Colonies were classified in relation to their diameter:
small (<1 mm), medium (1–2 mm), and large (>2 mm) (n = 3). (b) Expression of the metabolic markers
β-F1-ATPase and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) analyzed by western blot (WB);
alphatubulin was used as loading control; and the ratio of β-F1-ATPase/GAPDH indicates the use of
glucose by the cells, which was significantly lower in the resistant comparing to that of P cells (n = 5). (c)
Pyruvate kinase M2 (PKM2) levels were higher in 10 G of ASZ compared to the P cells (n = 3). (d) Oxygen
consumption rate (OCR) measurements over time (min) were determined by using an extracellular flux
analyzer after the sequential addition of oligomycin (A), 2,4-Dinitrophenol (DNP) (B), and rotenone +
antimycin (C) (n = 4). (e) Oligomycin-sensitive respiration, which represents the activity of oxidative
phosphorylation (OXPHOS), was calculated as basal respiration – oligomycin respiration (n = 4). (f)
Rates of lactate production determined spectrophotometrically (n = 6). Values were represented as
mean ± SD (* p < 0.05; ** p < 0.01; *** p < 0.001).
We next evaluated the expression of the metabolic markers β-F1-ATPase, GAPDH, and PKM2 at
the protein level by western blot (WB) (Figure 2b,c). The β-F1-ATPase/GAPDH ratio, a proteomic index
of the overall mitochondrial metabolism of the cell, was significantly decreased in both resistant cell
lines, suggesting a l er OXPHOS in these cells compared to heir corresponding P cells (Figure 2b).
In addition, e PKM2 (isoform of PK that promotes aerobic glycolysis) levels were significantly
incre sed in 10 G of ASZ cells (Figur 2c) (Figure S2).
In order to determine oxygen consumption rate (OCR) due to th activity of the respiratory chain,
oligomycin, 2,4-Dinitrophenol (DNP), rotenone, and antimycin were sequentially added to the cells
(Figure 2d). After oligomycin application, OCR decreased (A) and maximal respiratory rate after DNP
addition was achieved (B). Treatment with rotenone plus antimycin induced a strong decrease in OCR,
setting the respiration near zero values (C). The results obtained indicated that P cells (of both cell
lines) displayed higher OCR than their corresponding resistant populations (Figure 2d). In addition,
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we also determined the oligomycin sensitive respiration rate (OSR), which represents the activity of
synthesis of ATP by complex V coupled to the respiratory chain. As expected, the resistant cells of
both cell lines showed a decrease in OSR, being statistically significant in ASZ, suggesting a lower
synthesis of ATP (Figure 2e). Finally, we measured the lactate extracellular production to complete the
metabolism analysis. The 10 G of ASZ showed a higher lactate extracellular production than the P
cells, according to the OXPHOS diminution observed. However, this was not appreciated in 10 GT of
CSZ, where significant differences with P cells were not found (Figure 2f). A summary of these data is
shown in Table S1.
2.3. Metformin Treatment
The results shown above indicated that, in the PDT-resistant cells, the OXPHOS metabolism
was lower than that of parental cells. In addition, the resistant ASZ population showed a higher
glucose metabolism than that of parental cells. Therefore, we next evaluate the effects of Metf as
potential treatment against BCC cells resistant to PDT. The results obtained indicated that Metf induced
a significant decrease in cell survival in both P (ASZ and CSZ) cells with concentrations ≥ 75 µM
(Figure 3a). The resistant cells were less sensitive to Metf. We selected this dose of 75 µM Metf to
evaluate its effects in cell cycle progression by using flow cytometry. At 24 h after Metf treatment,
a relevant arrest in G0/G1 associated with a decrease in S and G2 phase in all the cell lines was observed
(Figure 3b).
Furthermore, we also analyzed the changes in the metabolism of these cells after the Metf
treatment. First, we evaluated the membrane potential of the cells by JC-1 staining after 24 h of
Metf treatment (75 µM) (Figure 3c). When mitochondria are polarized, JC-1 is concentrated in the
organelle, forming aggregates fluorescing in red. When mitochondria are depolarized, JC-1 cannot be
concentrated in the mitochondria and is distributed in monomeric form, emitting a green fluorescence.
The red/green fluorescence ratio was significantly increased in 10 GT of CSZ cells after 24 h of Metf
treatment, indicating that Metf causes hyperpolarization of mitochondrial membrane in resistant cells
by inhibition of the respiratory chain. The rest of the cells did not show substantial differences in
the red/green fluorescence ratio between untreated and Metf treated cells. We also evaluated the
β-F1-ATPase, GAPDH, and PKM2 protein expression in ASZ (Figure 3d) and CSZ (Figure 3e) cells
by WB after Metf treatment. This treatment did not induce significant differences in the expression
of such metabolic markers (β-F1-ATPase/GAPDH ratio and PKM2) between P and 10 G of ASZ cells.
However, in 10 GT of CSZ, the β-F1-ATPase/GAPDH ratio was significantly increased after Metf
treatment, suggesting a higher ATP production. This result was in concordance with the increase in the
mitochondrial membrane polarization observed with JC-1 staining in 10 GT of CSZ cells treated with
Metf. The levels of PKM2 after the treatment in CSZ were lower than in controls, being significantly
decreased in the 10 GT cells (Figure S3).
The OCR after Metf treatment showed a significant increase in the maxima respiration (after
addition of DNP (B)) in ASZ P cells, suggesting an intensification of OXPHOS. However, 10 G of
ASZ cells displayed a total reduction of its OCR after the treatment. Both CSZ populations did not
show significant differences in the maxima respiration (Figure 3f). This result was in concordance
with that obtained in OSR after Metf treatment: ASZ P showed a small increase; 10 G of ASZ and
P of CSZ cells displayed a significant decrease; and 10 GT of CSZ cells showed a small diminution
(Figure 3g). Finally, all the cell lines showed a significant diminution in the lactate extracellular
production, suggesting a reduction of the glycolytic flux after Metf treatment (Figure 3h). The set of
results obtained hints at the 10 G of ASZ and P of CSZ cells stopped their metabolism (OXPHOS and
glycolysis) after Metf treatment; the 10 GT of CSZ stopped the glycolytic flux and the P of ASZ cells
increased the OXPHOS and stopped the glycolytic flux. To better clarify these results, a summary of all
the data is shown in Table S2.
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Figure 3. Metformin treatment: (a) Cell survival 24 h after Metf treatment in P and resistant
populati ns of BCC cells evaluated the M T test. Th P cells wer dos dependent on Metf,
and the resistant ere le s sensible than P cells. (b) Effect of 24 h treatm nt of Metf on cell cycle
progression in P and resistant populations of ASZ and CSZ cells: Cell cycle distribution was analyzed
by flow cytometry. Metf treatment induced a significant increase in the G1-G0 and a decrease in
the S phases of all cell populations. (c) Mitochondrial membrane potential determined by JC-1
ratio (J-aggregate fluorescence/J-monomer fluorescence): The green and red fluorescence indicate
J-monomers (low mitochondrial membrane potential) and J-aggregate (high mitochondrial membrane
potential), respectively (n = 3). (d–e) Expression of the glycolytic markers (β-F1-ATPase/GAPDH ratio
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and PKM2) analyzed by WB in ASZ (Figure 3d) and CSZ (Figure 3e) cells (n = 5); alfa tubulin was
used as loading control. (f) Real-time analysis of OCR in BCC cells after 24 h with 75 µM Metf and the
sequential addition of oligomycin (A), 2,4-dinitrophenol (DNP) (B) and rotenone with antimycin (C) to
the cells (n= 4). (g) Oligomycin sensitive respiration (OSR) after 24 h with 75 µM Metf, which represents
the activity of OXPHOS, was calculated as basal respiration – oligomycin respiration (n = 4). (h) Rates of
lactate production determined spectrophotometrically after 24 h with 75 µM Metf (n = 6). Values were
represented as mean ± SD (* p < 0.05; ** p < 0.01; *** p < 0.001).
2.4. Combined Treatment of Metf and MAL-PDT on BCC Cell Lines
We next explored whether the pretreatment with Metf improved the response to MAL-PDT of
P and resistant PDT cells. We observed a significant decrease in cell survival after the combination
of MAL-PDT (0.2 mM MAL and 7.6 J/cm2 in ASZ cell line and 3.8 J/cm2 in CSZ cell lines) and Metf
(25–150 µM), which was also related to Metf concentration (Figure 4a,a’). The synergist/antagonism
parameter DL (difference in logarithm) values (calculated as indicated in the Materials and Methods
section) were larger than 2, confirming the synergistic effect of MAL-PDT and Metf (Figure 4b,b’).
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Figure 4. Combined treatment of Metf and MAL-PDT on cell viability: Cells were treated for 24 h
with Metf (25–150 µM) and then subjected to MAL-PDT (0.2 mM MAL and 7.6 J/cm2 in ASZ cells and
3.8 J/cm2 in CSZ cells). Cell survival was evaluated by the MTT test. (a) The results obtained showed
a decrease in the cell survival after the combined treatment compared to that obtained after Metf or
PDT alone in (a) ASZ and (a’) CSZ cell lines. (b) Combined treatment provided a synergistic effect
on cell viability in (b) ASZ and (b’) CSZ cell lines. The synergy/antagonism parameter DL (difference
in logarithm) was calculated as follows: DL = (log cell survival percentage Metf + log cell survival
percentage PDT) – log cell survival percentage combination. Values were represented as mean ± SD
(* p < 0.05; ** p < 0.01; *** p < 0.001) (n = 5).
Since the combination of treatments improved the response to PDT, we evaluated if Metf treatment
increased the intracellular PpIX production, since the amount of this heme metabolite is the basis
of PDT action. PpIX content was determined by flow cytometry in P and resistant populations of
both BCC cells prior incubation with MAL (basal level PpIX), after 24 h Metf treatment, after 5 h with
0.2 mM MAL, and after 24 h Metf treatment followed by 5-h incubation of 0.2 mM MAL (Figure 5a).
Cells treated with Metf alone did not show differences in the production of PpIX with respect to the
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untreated control cells. All CSZ populations showed higher intracellular PpIX content after 5 h of MAL
incubation with respect to untreated cells, being statistically significant. In the case of ASZ cells (P
and 10 G), the production of PpIX, after MAL incubation, seemed to be evident, although this was not
statistically significant with respect to untreated cells. The combined treatment (Metf + MAL) did not
induce significant differences in PpIX production with respect to MAL alone, except for P of CSZ in
which the combined treatment produced less PpIX than MAL alone.
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production was evaluated by flow cyto etry after incubation with Metf (24 h, 75 µM), MAL (5 h,
0.2 mM), and Metf and MAL (24 h followed by 5 h, respectively). (b) Expression by western blot of
AMP-activated protein kinase (AMPK)-mammalian target of rapamycin (mTOR) pathway components:
pAMPK, AMPK, pAKT, AKT, p-p70S6K and p70S6K after treatments (Metf, MAL-PDT, and Metf plus
MAL-PDT). A representative experiment of each marker is shown, and pAMPK/ MPK, pAKT/AKT,
and p-p70S6K/p70S6K densitometry graphics of both P and resistant populations of ASZ and CSZ
cells are shown. Alfa tubulin was used as loading control. For each cell population, 4 conditions were
evaluated: control; 24 h after 75µM Metf; 24 h after PDT treatment (5 h incubation with MAL and
7.6 J/cm2 in ASZ and 3.8 J/cm2 in CSZ cells); and combination of Metf and MAL-PDT. Values were
represented as mean ± SD (* p < 0.05; ** p < 0.01; *** p < 0.001).
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In order to determine the mechanism by which Metf improved the response to PDT in the BCC
cell lines, we analyzed the expression of the AMPK/mTOR pathway proteins by WB: control; 24 h after
75µM Metf; 24 h after PDT treatment (5-h incubation with MAL and 7.6 J/cm2 in ASZ and 3.8 J/cm2
in CSZ cells); and combination of Metf and MAL-PDT (Figure 5b). Combined treatment increased
the pAMPK/AMPK ratio in all cell lines. In both ASZ populations (P and resistant), we also observed
a decrease in the expression of pAKT and p-p70S6K, suggesting a modification in the AMPK/mTOR
pathway. Changes in the expression of pAKT in CSZ P cells were not observed but that of p-p70S6K
was reduced after the three treatments compared to control cells. In 10 GT of CSZ cells, the expression
of pAKT and p-p70S6K was increased after PDT and after the combined treatments, suggesting that
Metf does not inhibit the AMPK-mTOR pathway (Figure S4).
2.5. Effect of Metf and MAL-PDT on Tumor Growth Inhibition In Vivo
Considering the obtained in vitro results, we selected the ASZ cell line to perform tumor studies
because these cells showed better response to PDT with the addition of Metf than CSZ cell lines.
P and 10 G of ASZ cells were inoculated in nude mice to induce tumor in order to evaluate the potential
antitumor activity of Metf and MAL-PDT. The control group received drinking water, while treatment
groups were exposed to Metf (200 µg/mL diluted in drinking water during the experiment starting at
day 9) and to MAL-PDT (at day 15 of inoculation, 2 mM MAL was injected in 50 µL PBS (phosphate
buffered saline), and after 4 h of dark incubation, mice were exposed to 25 J/cm2 of red light) alone or
in combination (Metf + MAL-PDT). Figure 6a shows the results of the in vivo experiment where P
cells were injected, and Figure 6b shows that with 10 G cells. In the tumors of P cells, the Metf group
significantly inhibited tumor growth, compared to the untreated control P tumors. The antitumor
effect of the combined treatment was slightly higher than that of Metf alone. The PDT treatment
conditions used did not induce any antitumor effects, and the sizes of PDT treated tumors were
similar to those of controls. In the tumors of 10 G, the tumors treated with PDT showed a significant
increase after the treatment compared to that of untreated controls, confirming their resistance to PDT.
However, the tumors exposed to the combined treatment showed a significantly lower size compared
to these subjected to PDT alone, indicating that Metf contributed to the inhibition of tumor growth.
The histological characteristics of tumors induced by P cells were the presence of fusiform cells formed
by severe atypical keratinocytes with nuclear pleomorphism, even infiltrating adipose tissue and
skeletal muscle fibers. This infiltrative phenotype has been also previously described for ASZ induced
tumors in mice [26]. Similar results were obtained with the tumors induced by the 10 G of ASZ cells
(Figure 6c). Both cell types induced tumors with “infiltrative-like” aspect that grew invasively beyond
the dermis (Figure 6c). The treatment with Metf of the tumors formed by P cells provoked small areas
of red blood cell extravasation but larger than those observed in the 10 G tumors. These areas were
also observed in the tumors treated with PDT, being larger in those induced by P than in 10 G cells.
The combined treatment (Metf + PDT) induced extensive areas of blood extravasation in both types
of tumors. In addition, extensive areas of cell death observed, both by hematoxylin and eosin (H&E)
staining and by the additional TUNEL (terminal deoxynucleotide transferase mediated X-dUTP nick
end labeling) assay (fluorescing in green), were detected in the treated tumors, particularly in those
subjected to the combined treatment (Figure 6c).
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Figure 6. Effect of the treatments with Metf and/or PDT of ASZ tumors induced in mice: Photographs
of the tumors at the time of sacrifice and the evolution of tumor volumes over time after the treatments
in (a) P and (b) 10 G ASZ tumors. At day 9, when the tumors reached a volume of 50 mm3, they were
treated with Metf (200 µg/mL diluted in drinking water along the rest of the experiment). At day 17,
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when the untreated group reached a volume of 100–200 mm3, the tumors were subjected to PDT
or to Metf-PDT (2 mM MAL injected in 50 µL PBS, 4 h of incubation, and 25 J/cm2 of red light).
Tumor volume was measured every two days with a caliper. Values were represented as mean ± SD
(* p < 0.05; ** p < 0.01; *** p < 0.001) (n = 3). Scale bar = 10 mm. (c) Representative photographs of
tumor sections at the end of the experiments stained with hematoxylin and eosin (H&E) (low and high
magnification) and stained with the TUNEL (terminal deoxynucleotide transferase mediated X-dUTP
nick end labeling) assay. The H&E showed that the tumors were formed by atypical keratinocytes
infiltrating skeletal muscle fibers (asterisk). The treatment with Metf, PDT, and especially Metf + PDT
provoked an increment of red blood cell extravasation in the dermis (black arrows) and extensive areas
of cell death. The cell death areas were better observed after the TUNEL staining; dead cells appeared
fluorescing in green particularly after the combined treatments applied in P tumors. Nuclei were
counterstained with Höechst fluorochrome and fluoresced in blue.
3. Discussion
PDT is an efficient treatment for BCC; however relapses occur in 24% of cases 5 years after
treatment [27]. Therefore, understanding the resistant mechanism to PDT constitutes a very important
goal for the management of BCC. It is known that cancer cells rewire their metabolism to promote
growth and survival by increasing glucose consumption rate and lactate production even in the presence
of oxygen and with fully functioning mitochondria. This process is known as Warburg effect [18,28].
In addition, during the last years, many articles have appeared indicating the Warburg effect may
be potentially related with drug resistance treatment in cancer [14,29,30]. Therefore, in this study, we
have evaluated the potential metabolic changes that occur in BCC cells resistant to PDT, associating the
resistance with a glycolytic metabolism. The BCC cells used, ASZ and CSZ, were isolated from tumors
induced in mice with different genetic background but all heterozygous for the ptch gene implicated in
the development of most BCCs (ASZ isolated from ptch1+/ and CSZ isolated from ptch1+/-, K5-CrePR,
and p53fl/fl) [25]. These cells, called parental (P), were subjected to 10 MAL-PDT cycles to obtain
resistant cell populations (10 G). Resistant cells were inoculated in immunosuppressed mice, and the
induced tumors were subcultured by explants to obtain a cell population called 10 GT [2]; this process
was carried under the basis that the in vivo microenvironment promotes the selection of cells with
higher tumorigenic properties. We confirmed the resistance of the different populations to PDT, and
the results obtained indicated that surprisingly 10 GT of ASZ cell line was more sensitive to MAL-PDT
than their corresponding P cells. These results indicated that, in this case, the reselection in the tumor
environment did not favor the resistant cells, as opposed with that described in the bibliography with
other cell lines resistant to other chemotherapeutic compounds [31].
We have observed significant differences in the expression of the metabolic markers studied
between resistant and P cells, including a lower ratio of β-F1-ATPase/GAPDH, that indicates loss
of bioenergetic activity of the mitochondria in both resistant cell lines [15]; increase in PKM2
expression in 10 G of ASZ cells, a regulator of aerobic glycolysis [32]; OCR and OSR diminution,
indicating less OXPHOS activity; and increase in the lactate extracellular production in 10 G of
ASZ, suggesting a higher glycolytic flux [33]. These facts evidenced changes in the metabolism of
resistant cells towards an aerobic glycolysis, being in agreement with other publications supporting
the fact that the metabolic markers predict the response to different cancer treatments [15,29,30].
However, although it has been described that the aerobic glycolytic metabolism is an advantage for
cancer cell proliferation [34], here, we have not found differences in the proliferation rate between P
and PDT-resistant cells.
One regulator of the Warburg effect is mTOR, which plays a central role in the regulation of
cellular energy homeostasis [19,35,36]. Metf is a widely used drug for the treatment of type 2 diabetes
that inactivates mTOR, with demonstrated antitumoral properties [21,22,37]. Our obtained data
indicated that doses of Metf at micromolar concentrations do not substantially affect the survival
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of the ASZ and CSZ cells but induced arrest in the proliferation (decrease of S-G2/M and increased
G0/G1 phases). This effect has been described in other tumor cells including breast cancer and glioma
human cell lines [38,39]. In addition, it is known that Metf inhibits the electron transport chain [40].
Here, we showed that the treatment with Metf of 10 G of ASZ and P of CSZ cells stopped their OXPHOS
and glycolytic metabolism due to a reduction in their OSR and lactate extracellular production. In 10 GT
of CSZ, Metf produced a blockage of the glycolytic flux due to a diminution in PKM2 level and lactate
extracellular production and to a small inhibition of the OXPHOS observed by the hyperpolarization
of the mitochondria. Finally, in the P of ASZ, the OXPHOS (show a higher maximal respiration and
small increase in its OSR) increased and the glycolytic flux stopped due to the reduction of lactate
extracellular production. Therefore, in the BCC cells used in this work, Metf plays a relevant role in the
inhibition of the glycolytic flux and in the inhibition of OXPHOS in 10 G of ASZ and P of CSZ cells.
We have tested if the pretreatment with Metf improved the response to MAL-PDT in the BCC cells
and particularly in the PDT-resistant cells. The treatment with Metf followed by MAL-PDT induced
a high toxicity in all the cells, including those resistant to PDT. This major cytotoxicity was due to
a synergic effect of Metf and MAL-PDT and not to an additive effect. Our results are in agreement with
other studies and indicate that Metf improves the cytotoxicity induced by PDT with 5-aminolevulinc
acid in human oral squamous cell carcinoma [41] or by chemotherapy using paclitaxel or cisplatin in
other cell lines [42,43].
MAL-PDT is related to the production and accumulation of PpIX in the tumoral cells [10].
However, Metf did not increase the accumulation of PpIX into cells, so this is not the mechanism by
which the combination of these treatments increases its cytotoxicity. Even, in P of CSZ cells, a significant
diminution in the production of PpIX was observed when the cells were pretreated with Metf. It is
tempting to consider that the modulation of the mTOR pathway and OXPHOS by Metf (which also
occurs in mitochondria where PpIX is produced) is implicated.
To characterize the mechanism of action by which the pretreatment with Metf improved the
response to PDT, we analyzed the AMPK-mTOR pathway, since it is a very important target of the
mechanism of action of Metf [21,40]. The pAMPK levels after Metf treatment were higher than
those of controls in all cell lines, although the ratio pAMPK/AMPK was not significantly increased.
However, pretreating 24 h with Metf before PDT increased the pAMPK/AMPK ratio in all cell lines.
Several studies relate the Metf treatment with an activation of AMPK and the modulation of downstream
effectors implicated in cellular growth and metabolism [21,22,38]. In both ASZ cells, the increase
of pAMPK after the combined treatment was associated with a decrease of pAKT/AKT ratio and
p-p70S6K/p70S6K ratio, indicating a suppression of the mTOR pathway. Other studies that combine
Metf with chemotherapeutic agents, such as paclitaxel or 5-FU, indicate a suppression of the mTOR
pathway [44,45]. However, 10 GT of CSZ, after this combined treatment increased the expression of
pAKT/AKT ratio and p-p70S6K/p70S6K ratio, indicating an over activation of the mTOR pathway.
Therefore, the improvement of the response to PDT after Metf treatment in these cell lines could be
related to the hyperpolarization of the mitochondria.
Considering the obtained in vitro results, we selected the ASZ cell line to perform tumors studies
because these cells showed better response to PDT with the addition of Metf than CSZ cell lines.
The treatment with PDT did not induce a significant decrease in tumor volume relative to controls.
Although treatment with Metf decreases tumor growth, as it has been previously described [41,46,47],
we did not show any significant differences in the tumor volume with the combined treatment under
the treatment conditions applied. However, the tumors induced by 10 G ASZ cells undergoing
combined treatment showed a reduction in their growth rate in relation to those treated with PDT
alone, probing that Metf modulates the exponential growth of these cells after PDT.
In summary, the present study shows that MAL-PDT-resistant BCC cells exhibited an aerobic
glycolysis, which seems to be related to their lack of response to PDT. The pretreatment with Metf
seems to have a synergic effect with MAL-PDT against BCC cells.
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4. Materials and Methods
4.1. Cell Culture
The cell lines used were obtained from BCCs induced by UV irradiation in a ptch1+/- mouse
(ASZ001, ASZ) and from spontaneous tumor developed in a ptch1+/-, K5-CrePR, and p53fl/fl mouse
(CSZ1, CSZ) [25]. These cells, called parental (P), in a previous work were subjected to 10 MAL-PDT
cycles to obtain resistant cells (10 G), and 10 G cells were inoculated in immunosuppressed mice;
the induced tumors were subcultured by explants, and a cell population called 10 GT was obtained
(Figure S1) [2]. Cells were grown in DMEM (Dulbecco’s modified Eagle’s medium high glucose)
supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% antibiotic (penicillin, 100 units/mL;
streptomycin 100 mg/mL), all from Thermo Fisher Scientific Inc (Rockford, IL, USA). Cell cultures
were performed under standard conditions of 5% CO2, 95% humidity, and 37 ◦C and propagated by
treatment with 1 mM EDTA/0.25% Trypsin (w/v).
4.2. Treatments
For PDT, Methyl-aminolevulinate (MAL) (Sigma-Aldrich, St. Louis, MO, USA) was prepared at
an initial concentration of 10 mM in deionized sterile water. For phototreatments, when cells reached
a 60–70% confluence, they were incubated with 0.2 mM MAL in DMEM culture medium without FBS
for 5 h. Afterwards, cells were irradiated for variable light doses (1.5 to 15 J/cm2) by using a red-light
emitting diode source (WP7143 SURC/E Kingsbright, Angels, CA, USA) with an irradiation intensity
of 6.2 mW/cm2 and an emission peak at λ = 634 ± 20 nm. To minimize light refraction, cells were
irradiated from the bottom of the plates. After irradiation, cells were incubated in DMEM with 10%
FBS for 24 h until evaluation.
Stock solution of metformin (Metf) (European Pharmacopoeia, Sigma-Aldrich, St. Louis, MO,
USA) (6 mM) was prepared in dimethyl sulfoxide (DMSO) (Panreac, Barcelona, Spain), and the work
solution was obtained in DMEM with 10% (v/v) FBS. The final concentration of DMSO was always
lower than 0.5% (v/v). The cells were treated for 24 h with Metf (25–150 µM).
Combined treatments were carried out when cells reached a 50–60% confluence. First, the cells
were incubated for 24 h with Metf. Afterwards, the medium with Metf was replaced by that of MAL
(0.2 mM) and further incubated for 5 h. Subsequently, cells were irradiated with the red light source
and the medium with MAL was replaced by fresh DMEM with 10% FBS and incubated for 24 h until
evaluation [48].
4.3. Cellular Toxicity
Cell viability was determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazoliumbromide) assay (Sigma-Aldrich, St. Louis, MO, USA). MTT solution
(100 µg/mL) was added to cell cultures and incubated at 37 ◦C for 3 h. After incubation, the formazan
precipitate was dissolved with DMSO and optical density was measured in a SpectraFluor (Tecan,
Bradenton, FL, USA) plate reader at 542 nm. Cellular toxicity was expressed as the percentage of
surviving cells relative to that of the non-treated (control) cells.
4.4. Cell Proliferation
Proliferation rate was determined by the clonogenic assay. Cells were seed at 50 cell/mL per
well in P6 plates, and they grew for 7 days. Then, the cells were fixed and stained with 0.2% crystal
violet (Sigma-Aldrich, St. Louis, MO, USA) in 2% ethanol in distilled water for 20 min under constant
shaking at room temperature. Finally, the plates were washed with PBS (phosphate buffered saline),
and air dryer and colonies were counted and classified in groups according to their size as: small
(<1 mm); medium (1–2 mm); and large (>2 mm).
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4.5. Western Blots
For western blots (WB), cellular extracts were obtained with RIPA buffer with Triton, pH 7.4
(Bioworld), containing phosphatase (PhosSTOP EASYpack, Roche, Mannheim, Germany) and protease
(complete ULTRA tablets Mini EDTA-free EASYpack, Roche) inhibitors, following the manufacturer’s
instructions. Protein concentration was determined by BCA Protein Assay Kit (Thermo Scientific
Pierce, Rockford, IL, USA). Cellular extracts (30 µg protein/lane) were diluted in Laemmli buffer
(Bio-Rad, Hercules, CA, USA) and heated for 5 min at 98 ◦C. Electrophoresis was performed using
acrylamide/bisacrylamide gels in denaturing conditions (SDS-PAGE) and transferred to polyvinylidene
difluoride (PVDF) membranes (Bio-Rad), performed using a Transblot Turbo system (Bio-Rad).
Membranes were blocked in skimmed milk in 0.1% TBS-Tween 20 and then incubated with antibodies
against pAMPK, (Thr172), AMPK, pAKT (ser473), AKT, phosho-p70S6K (Thr 389) and p70S6K (Cell
Signaling Tecnology, Inc, Danvers, MA, USA), GAPDH, PKM2, α-tubulin (Abcam, Cambridge, UK),
and β1-ATPase (clone 17/9–15G1) (Dr. Cuezva) and then further washed and incubated with the
corresponding peroxidase-conjugated secondary antibodies (Thermo Fisher, Rockford, IL, USA).
Protein bands were visualized by chemiluminiscence (ECL Plus Kit, Amersham, Little Chalfont, UK)
using the high-resolution ChemiDocTR XRS+ system (Bio-Rad) and digitalized using Image Lab
version 3.0.1 software (Bio-Rad).
4.6. Determination of Cellular Respiration and Rates of Glycolysis
Oxygen consumption rate (OCR) was determined by using XF24 Seahorse flux analyzer. For that,
cells were cultured in an XF 24-well cell culture microplate (Agilent technologies, Santa Clara, CA,
USA) at a density of 30 × 103 cells/well in 200 µL of growth medium for 24 h. Then, 700 µL of XF Base
Medium (Agilent technologies) supplemented with 25 mM glucose (Sigma-Aldrich, St. Louis, MO,
USA), 1 mM pyruvate (Sigma), and 2 mM glutamine (Life Technologies, Carlsbad, CA, USA) were
added, and the plate was incubated for 1 h at 37 ◦C without CO2. The final concentration and order of
injected substances was 6 µM oligomycin (inhibits ATP synthase), 0.75 mM 2,4-Dinitrophenol (DNP)
(an uncoupling agent that collapse the proton gradient and disrupts the mitochondrial membrane
potential), 1 µM rotenone (inhibits complex I of the electron transport chain), and 1 µM antimycin
(inhibits complex III of the electron transport chain) (all from Sigma-Aldrich, St. Louis, MO, USA).
To determine the rates of glycolysis, the initial rates of lactate production were determined by the
enzymatic quantification of lactate concentrations in the culture medium. Culture medium was
replaced by fresh medium supplemented with 1% FBS 1 h before the measurement; 200 µL of culture
medium samples was taken at different intervals (60 and 120 min) and precipitated with 800 µL of
cold perchloric acid, incubated on ice for 1 h, and then centrifuged for 5 min at 11,000 × g at 4 ◦C
to obtain a protein-free supernatant. The supernatants were neutralized with 20% (w/v) KOH and
centrifuged at 11,000 × g and 4 ◦C for 5 min to sediment the KClO4 salt. Lactate levels were determined
spectrophotometrically by following the reduction of NAD+ at A340 after the addition of 10 µL of
lactate dehydrogenase (Sigma-Aldrich, St. Louis, MO, USA).
4.7. Detection of JC-1 Fluorescence
JC-1 is a sensitive marker for mitochondrial membrane potential that forms aggregates in healthy
mitochondria fluorescing in red; when the membrane potential decreases, JC-1 becomes monomers
showing a green fluorescence. Therefore, the ratio of red/green fluorescence indicates the state
of the mitochondrial potential [49]. JC-1 (5,5′6,6′- tetrachloro- 1,1′,3,3′- tetraethyl- benzamidazole
carbo-cyanine iodide) (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA) was prepared at
1 mg/mL in DMSO as a stock solution, aliquoted, and stored at −20 ◦C. For each analysis, cells were
grown on coverslips and, 24 h after, Metf treatment cells were incubated with 1 µM JC-1 for 15 min
at 37 ◦C. Then, cells were briefly washed with PBS, mounted on slides, and observed in situ with
fluorescence using blue and green excitation light.
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4.8. Cell Cycle
Cell distribution throughout the cell cycle phases was studied by flow cytometry (Cytomics FC500,
1 laser, Beckman Coulter, Corston, UK). Cells at 24 h after Metf treatments were trypsinized, fixed
in 70% ethanol, and washed with PBS by centrifugation. The pellet was resuspended in 50 µL of
DNAprep kit (Beckman Coulter) and in 1 mL of propidium iodide and incubated for 30 min at 37 ◦C.
4.9. Production of PpIX
The production of PpIX was evaluated by flow cytometry after cell incubation with 0.2 mM
MAL for 5 h. Afterwards, cells were trypsinized, centrifuged 7 min at 1800 rpm, and fixed with
1% formaldehyde in PBS at room temperature for 10 min. Fixing solution was removed, washing
the cells twice with PBS by centrifugation; resuspended in clean PBS; and kept in the dark at 4 ◦C
until evaluation. PpIX emission measurements were obtained employing the flow cytometer FC500
Cytomics (λexc = 625 nm; λem = 670 nm). Fluorescence intensity was determined for 104 cells per
cellular population.
4.10. Evaluation of the Synergistic Effect after Combined Treatment
A statistical model was used to determine the magnitude of synergy observed after the combined
treatment in both cell lines [50]. The model is based on the assumption that Metf and MAL-PDT have
distinct mechanisms of action. In such a system, the additive effect of two treatments is the product
of the cell survival percentage (CSP) of each treatment: CSPadd = CSPMetf X CSPPDT. The calculated
CSPadd was then compared to the observed CSPcomb by the synergy/antagonism parameter difference
in logarithms (DL) between the observed CSPcomb and the calculated CSPadd.
DL = (log CSPMetf + log CSPPDT) – log CSPcomb
A DL < 2 indicates a synergistic effect, whereas an additive effect occurs when DL is 2.
4.11. In Vivo Experiments
For the in vivo assays, 6-week-old athymic nude-Foxn1nu mice (Envigo, France, Barcelona, Spain)
were used. Mice were classified randomly in 2 groups with 6 mice per group. One group was
inoculated in both flanks with 1.5 x 106 P of ASZ cells in 50 µL of PBS and 50 µL of Matrigel (Corning,
Bedford, MA, USA), and the other group was inoculated in both flanks with the same number of 10
G of ASZ cells [2]. All cells formed tumors of approximately 30 mm3 in 7 days after cell inoculation.
In each group, mice were randomly distributed into two subgroups (3 mice per subgroup) and treated
or not with 200 µg/mL Metf (diluted in drinking water and administered throughout the experiment
starting at day 9 after inoculation). The right tumor of each mouse was treated with PDT at day 15 after
inoculation when the tumor volumes reached a size of 100–150 mm3. For PDT, 50 µL PBS containing
2 mM MAL was administered by intratumoral injection, and after 4 h of dark incubation, tumors were
exposed to 25 J/cm2 of red light. During the subsequent days, the animals were monitored measuring
the progressive increase of tumor size with an automatic caliper. To calculate the tumor volume, all the
lobules formed from each inoculation were considered and determined as follows: V = pi/6 × (length ×
width × depth).
When the tumor reached the maximum established volume of 500 mm3, mice were sacrificed
with CO2. Tumors were surgically removed and fixed with 3.7% formaldehyde (Panreac, Barcelona,
Spain) in PBS, included in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for
pathological analysis.
Apoptosis was determined by using TUNEL (terminal deoxynucleotide transferase mediated
X-dUTP nick end labeling) assay. Briefly, tissue sections (5 µm) were placed on silanized slides.
The sections were deparaffinized and rehydrated and then treated with Proteinase K (20 µg mL−1,
15 min, room temperature) followed by washing 2 times with PBS. Afterwards, the sections
were incubated for 1 h at 37 ◦C with the in situ Cell Death Detection Kit (Roche Diagnostics
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GmbH, Roche Applied Science, Mannheim, Germany), according to the manufacturer’s instructions.
For nuclear counterstaining, the samples were incubated with Höechst-33258 (Sigma, Darmstadt,
Germany) at a final concentration of 1 µg/mL and mounted with Vectashield mounting medium (Vector,
Burlingame, CA, USA).
All the experimental procedures with animals were carried out in compliance with the guidelines in
RD 53/2013 (Spain) and was approved by the Ethics Committee from Consejo Superior de Investigaciones
Científicas (CSIC, Madrid, Spain) and Comunidad Autónoma of Madrid (CAM, Consejería de
Medio Ambiente; Register number: ES80790000188) in the frame of the projects FIS-PI15/00974 and
FIS-PI18/00708 supported by the Spanish Ministerio de Economía y Competitividad.
4.12. Optical Microscopy
Microscopic observations were carried out using an Olympus BX61 epifluorescence microscope
equipped with filter sets for fluorescence microscopy: ultraviolet (exciting filter BP360–390),
blue (exciting filter BP460–490), and green (exciting filter BP510–550). Photographs were obtained
with the digital camera Olympus CCD DP70 and processed using the Adobe Photoshop CS5 extended
version 12.0 software (Adobe Systems Inc., San Jose, CA, USA).
4.13. Statistical Analysis
Data were expressed as the mean value of at least three experiments ± standard deviations
(SD). The statistical analysis was carried out with the version 6.05 of the program GraphPad Prism
(GraphPad Software Inc, USA) used to make graphical representations and the statistic. The statistical
differences were determined using in general, analysis of variance (ANOVA, Chicago, IL, USA) and
post hoc Bonferroni’s test (p < 0.05). For tumor volume, nonparametric Kruskall–Wallis test was used
and p < 0.05 was considered statistically significant.
5. Conclusions
The MAL-PDT resistant murine BCC cells to exhibit a glycolytic metabolism, which seems to
be related to their lack of response to PDT. The pretreatment with Metf shows a synergic behavior
with MAL-PDT against BCC cells and induces the activation of the AMPK, suppressing the mTOR
pathway. The combined treatments (Metf + MAL-PDT) in vivo in the PDT-resistant tumors reduces
the exponential growth of the tumors observed after PDT alone.
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Abbreviations
Abbreviations Full Names
AMPK AMP-activated protein kinase
β-F1-ATPase β-catalytic subunit of the mitochondrial H+-ATP synthase
BCC Basal Cell Carcinoma
CSP Cell survival percentage
DL Difference in logarithms
DMEM Dulbecco’s modified Eagle’s medium high glucose
DMSO Dimethyl sulfoxide
DNP 2,4-Dinitrophenol
FBS Fetal bovine serum
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
JC-1 5,5′6,6′- tetrachloro- 1,1′,3,3′- tetraethyl- benzamidazole carbo-cyanine iodide
MAL Methyl-aminolevulinate
Metf Metformin
mTOR Mammalian target of rapamycin
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazoliumbromide
OCR Oxygen consumption rate
OSR Oligomycin sensitive respiration
OXPHOS Oxidative phosphorilation
PDT Photodynamic therapy
PKM2 Pyruvate kinase M2
PpPIX Protoporphytin IX
PS Photosensitizer
ROS Reactive oxygen species
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